Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/163131
Title: Binding properties of the anti-TB drugs bedaquiline and TBAJ-876 to a mycobacterial F-ATP synthase
Authors: Krah, Alexander
Grüber, Gerhard
Bond, Peter. J.
Keywords: Science::Biological sciences::Biophysics
Issue Date: 2022
Source: Krah, A., Grüber, G. & Bond, P. J. (2022). Binding properties of the anti-TB drugs bedaquiline and TBAJ-876 to a mycobacterial F-ATP synthase. Current Research In Structural Biology, 4, 278-284. https://dx.doi.org/10.1016/j.crstbi.2022.09.001
Project: NRF-CRP18-2017-01
Journal: Current Research In Structural Biology
Abstract: Tuberculosis (TB), the deadly disease caused by Mycobacterium tuberculosis (Mtb), kills more people worldwide than any other bacterial infectious disease. There has been a recent resurgence of TB drug discovery activities, resulting in the identification of a number of novel enzyme inhibitors. Many of these inhibitors target the electron transport chain complexes and the F1FO-ATP synthase; these enzymes represent new target spaces for drug discovery, since the generation of ATP is essential for the bacterial pathogen’s physiology, persistence, and pathogenicity. The anti-TB drug bedaquiline (BDQ) targets the Mtb F-ATP synthase and is used as salvage therapy against this disease. Medicinal chemistry efforts to improve the physio-chemical properties of BDQ resulted in the discovery of 3,5-dialkoxypyridine (DARQ) analogues to which TBAJ-876 belongs. TBAJ-876, a clinical development candidate, shows attractive in vitro and in vivo antitubercular activity. Both BDQ and TBAJ-876 inhibit the mycobacterial F1FO-ATP synthase by stopping rotation of the c-ring turbine within the FO domain, thereby preventing proton translocation and ATP synthesis to occur. While structural data for the BDQ bound state are available, no structural information about TBAJ-876 binding have been described. In this study, we show how TBAJ-876 binds to the FO domain of the M. smegmatis F1FO-ATP synthase. We further calculate the binding free energy of both drugs bound to their target and predict an increased affinity of TBAJ-876 for the FO domain. This approach will be useful in future efforts to design new and highly potent DARQ analogs targeting F-ATP synthases of Mtb, nontuberculosis mycobacteria (NTM) as well as the M. leprosis complex.
URI: https://hdl.handle.net/10356/163131
ISSN: 2665-928X
DOI: 10.1016/j.crstbi.2022.09.001
Rights: © 2022 The Authors. All rights reserved. This paper was published by Elsevier B.V. in Current Research in Structural Biology and is made available with permission of The Authors.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:SBS Journal Articles

Files in This Item:
File Description SizeFormat 
BDQ_ATP_synthase_Curr Res Struct Biology.pdf1.35 MBAdobe PDFView/Open

Page view(s)

10
Updated on Dec 3, 2022

Download(s)

2
Updated on Dec 3, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.